缩短ANCA相关血管炎糖皮质激素疗程:一项先导试验
该先导试验纳入20例活动性ANCA相关血管炎患者,给予8周泼尼松减量联合利妥昔单抗375mg/m2每周一次共4周方案。70%患者达到24周完全缓解,与RAVE试验历史对照相似(校正OR 1.31 [0.26-6.56]),不良事件中位数更少(2 vs 8,p < 0.001)但复发率更高(30% vs 7%,p = 0.03)。作者认为需在特定人群进一步研究该方案。
要点
- 8周泼尼松减量联合利妥昔单抗可使70%活动性ANCA相关血管炎患者达到24周完全缓解。
- 与RAVE历史对照相比完全缓解率相似(校正OR 1.31 [0.26-6.56]),不良事件中位数更少(2 vs 8,p < 0.001)。
- 复发率高于RAVE对照(30% vs 7%,p = 0.03),复发多发生于入组时有严重血管炎表现者。
核心结论
- 8周泼尼松联合利妥昔单抗方案的6个月完全缓解率与RAVE试验相似,不良事件更少但复发更频繁。
- 作者认为需在特定患者人群中进一步研究该方案。
研究设计与样本
- 先导试验,纳入20例活动性ANCA相关血管炎患者。
- 给予8周泼尼松减量联合利妥昔单抗375mg/m2每周一次共4周。
- 排除需要机械通气的严重肾小球肾炎或弥漫性肺泡出血患者。
- 主要终点为24周完全缓解(无疾病活动且停用泼尼松且无中间复发)。
- 次要分析将研究结局与RAVE试验历史对照进行比较。
主要发现
- 20例患者中14例(70%)达到主要终点。
- 与RAVE试验对照相比达到主要终点的校正OR为1.31 [0.26-6.56]。
- 每例患者不良事件中位数本研究为2 vs RAVE对照为8(p < 0.001)。
- 复发率本研究为30% vs RAVE对照为7%(p = 0.03)。
- 多数复发发生于入组时有严重血管炎表现的患者,两组疾病损伤无差异。
局限性
- 作者结论指出需在特定患者人群中进一步研究该方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Therapeutic advances in ANCA-associated vasculitis (AAV) have improved patient survival, but mortality rates remain higher than the general population. Glucocorticoids contribute to AAV morbidity and mortality. We examined whether an 8-week glucocorticoid course in combination with rituximab (RTX) would induce disease remission in patients with AAV. METHODS: Patients with active AAV received an 8-week prednisone taper and RTX 375mg/m2 weekly for 4 weeks. Patients with severe glomerulonephritis or diffuse alveolar hemorrhage requiring mechanical ventilation were excluded. In-person and telephone visits were scheduled for disease activity assessment. The primary endpoint was complete remission at 24 weeks (no disease activity while being off prednisone with no intercedent relapses). Secondary analysis included comparing study outcomes to historical controls from the Rituximab in AAV (RAVE) trial. RESULTS: Fourteen of 20 patients (70%) achieved the primary outcome. The patients in our trial achieved the primary outcome at a rate similar to that of controls from the RAVE trial (adjusted OR 1.31 [0.26-6.56]), had fewer median adverse events per patient (2 versus 8, p < 0.001) but were more likely to relapse (30% versus 7%, p = 0.03). Most relapses occurred in patients who had severe vasculitic manifestations at trial entry. Disease damage did not differ between the two trial populations. CONCLUSION: An 8-week course of prednisone with RTX resulted in a similar rate of complete remission at 6 months as in the RAVE trial, with fewer adverse events but more frequent relapses. Further study of this protocol is warranted in selected patient populations.
引用
- Miloslavsky EM, Niles JL, Wallace ZS, et al. Reducing glucocorticoid duration in ANCA-associated vasculitis: A pilot trial. Semin Arthritis Rheum. 2018. PMID: 29530330. doi:10.1016/j.semarthrit.2018.01.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。